Emcure Pharma Receives USFDA Establishment Inspection Report for Sanand Facility
New Delhi: Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat.
The USFDA has classified the inspection status of the facility as Voluntary Action Indicated (VAI), and the inspection has consequently been closed.
The development was disclosed by Emcure Pharmaceuticals in a communication to the National Stock Exchange of India Limited and BSE Limited dated August 8, 2026. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referred to its earlier intimation dated May 16, 2026, concerning the USFDA inspection at the facility.
The USFDA had conducted the inspection at Emcure's formulations facility located at G.I.D.C., Taluka-Sanand, Ahmedabad – 382110, Gujarat, from May 6, 2026, to May 15, 2026. The latest company disclosure confirms that the Establishment Inspection Report has now been received and that the regulatory inspection has been classified as VAI.
With the VAI classification, the inspection stands closed, according to the company's regulatory filing. The company’s disclosure specifically concerns the USFDA inspection of its Sanand formulations facility and the subsequent receipt of the Establishment Inspection Report (EIR) from the USFDA. The inspection status has been classified as Voluntary Action Indicated (VAI) and the inspection has been formally closed.
